Submissions from 2022
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial., Heather L. McArthur, David B. Page, and See all authors in comments
A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer., Heather L. McArthur, David B Page, and See full list of authors in comments
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial., Heather L. McArthur, David B Page, and See full list of authors in comments
A Single Arm Phase 2 Study of Peri-Operative Checkpoint-Mediated Immune Therapy and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer, Heather McArthur, David B. Page, Staci Mellinger, Nicole Fredrich, Nicole Moxon, and See all authors in comments
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group., Ranee Mehra, Richard Bryan Bell, and See full list of authors in comments
Immunological profiling of tumor-infiltrating CD8+ T lymphocytes in primary non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer (BCa), and renal cell cancers (RCC)., W Miller, William L. Redmond, and See full list of authors in comments
CT041 - Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Michael Millward, Rachel E Sanborn, and See full list of authors in comments
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study., Bernhard Mlecnik, Toshihiko Torigoe, Gabriela Bindea, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Yoshihiko Hirohashi, Tomohisa Furuhata, Ichiro Takemasa, Prabhudas Patel, Hemangini Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Takayuki Yoshino, Hiroya Taniguchi, Carlo Bifulco, Alessandro Lugli, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Florence Marliot, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn Van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Yutaka Kawakami, and Jérôme Galon
CT250 / 11 - A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer, Aung Naing, Brendan Curti, and See full list of authors in comments
The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery., David B Page
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases., David B Page, Kathryn Beal, Stefanie N Linch, Kateri Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A Barker, Adi Diab, Larry Norton, and Heather L McArthur
1296 Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC), Ravi Parikh, Brendan Curti, Roshanthi Weerasinghe, and See all authors in comments
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck., Brian J Park, Austin K Mattox, Daniel Clayburgh, Mihir Patel, R Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T Lin, William C Faquin, Peter M Sadow, and Sara I Pai
Real-World Evidence Insights in Cancer Research and Care, Brian D. Piening
Pathogenic fusion detection in solid malignancies utilizing RNA-DNA based comprehensive genomic profiling (CGP) testing., Brian D. Piening, Alexa K Dowdell, Ryan Meng, Ann Vita, Roshanthi Weerasinghe, Alisha Stein, Bela Bapat, Brock Shroeder, Shu-Ching Chang, Lauren Harold, Mark Schmidt, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, and Carlo Bifulco
Elucidating Diversity in Obesity-Related Phenotypes Using Longitudinal and Multi-omic Approaches, Brian D. Piening, Alexa K Dowdell, and Michael P. Snyder
Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection., Brian D. Piening, Alexa K Dowdell, Mengqi Zhang, Bao-Li Loza, David Walls, Hui Gao, Maede Mohebnasab, Yun Rose Li, Eric Elftmann, Eric Wei, Divya Gandla, Hetal Lad, Hassan Chaib, Nancy K Sweitzer, Mario Deng, Alexandre C Pereira, Martin Cadeiras, Abraham Shaked, Michael P Snyder, and Brendan J Keating
Design and Implementation of a Decentralized Virtual Molecular Tumor Board across a Large, Diverse Community Health System, Brian Piening, Patrick Foley, K Matlock, H Wright, Lauren Harold, Roshanthi Weerasinghe, A Viita, C Moung-Wen, Jacob Abel, Vassil Kaimaktchiev, A Dowdell, Ryan Meng, Walter Urba, G Srinivasa, Philip Gold, Gina Vaccaro, and Carlo Bifulco
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study., John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, and Gregory L Beatty
CT209 / 9 - A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348), John Powderly, Matthew H Taylor, and See full list of authors in comments
Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy, William L. Redmond
Novel mechanisms to augment the efficacy of cancer immunotherapy, William L. Redmond
Multimodal single-cell analysis of human tumor infiltrating immune cells across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapeutic strategies., William L. Redmond and See full list of authors in comments
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8, Annah S Rolig, Daniel Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, and William L. Redmond
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs., AS Rolig, William L. Redmond, and See full list of authors in comments
Vaccines and emerging immunotherapy approaches for NSCLC, Rachel Sanborn
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors., Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, and Tibor Keler
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer, Rachel E Sanborn and See full list of authors in comments
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study., Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel Gupta, Ronald Dubowy, Aleco D'Andrea, Lei Wang, Ken Ogasawara, Jerill Thorpe, and Leo I Gordon
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01), Manish Sharma, Brendan Curti, and See all authors in comments
Immunotherapy in head and neck squamous cell carcinoma: a narrative review., Shay Sharon and R Bryan Bell
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2., Catherine A. Shu, Rachel E Sanborn, and See full list of authors in comments
549 Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer., Sasha Stanton, Jennifer Childs, Doreen Higgins, Angela Kask, Yi Yang, and Mary Disis
Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha E. Stanton and See all authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Lisa Diana MacDonald, Staci Mellinger, Nikki Moxon, Tracy L. Kelly, Heather Ann Hirsch, Stephan Fiset, Kristina H Young, and David B Page
646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton, David Page, Kristina Young, and See all authors in comments
Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC, Sasha Stanton, Jason Schlumbohm, and Mary L. Disis
3380 / 8 - Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer, Sasha Stanton and See full list of authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments
647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma, Don Stevens, Rachel Sanborn, and See all authors in comments
TP022/#1424 A phase I/II study evaluating intraperitoneal GEN-1 in combination with neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer, Premal Thaker, Melanie Bergman, and See all authors in comments
409 Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762, Colin Thalhofer, Tarsem Moudgil, Bernard A Fox, Nelson Sanjuan Silva, Eric Tran, and See all authors in comments
Targeting mutant KRAS with adoptive T-cell therapy, E Tran
TCR-gene therapy targeting mutant KRAS, E Tran
Targeting mutant KRAS with TCR-gene therapy, Eric Tran
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply., Eric Tran, Walter Urba, and Rom Leidner
Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment., Rieneke van de Ven, Carlo Bifulco, Jason J Luke, and Sarah E Church
Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function, Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S Tykodi, Evan T Hall, David R Byrd, John A Thompson, Venu G Pillarisetty, Thomas Duhen, A McGarry Houghton, Evan Newell, Raphael Gottardo, and Stanley R Riddell
Geno4ME: establishment of an equitable whole-genome sequencing-based platform for clinical screening in a large healthcare system, Josiah Wagner, I A. Lucas-Beckett, K R. Emery, B A. Cosgrove, John T. Welle, K Jade, N D. Wagner, J Rinaldi, Lindsay Dickey, K G. Jones, L Yuan, E M. Shull, J Clemens, Keri Vartanian, A T. Magis, M B. Campbell, Brian Piening, Carlo Bifulco, and Ora K. Gordon
Clinical Performance of Comprehensive Genomic Profiling Using a Wide Range of Input Quantities and Solid Tumor Tissue Types, Josiah Wagner, S Reynolds, A Dowdell, E Shull, J Welle, M Pukay, R Rattray, C Moung-Wen, T Ward, M Campbell, C Bifulco, and B Piening
Streamlining Solid Tumor Comprehensive Genomic Profiling Workflows Using Learned Variant and Sequencing Noise Autoclassification, Thomas Ward, S Reynolds, J Wagner, N Naidoo, E Shull, John Welle, R Rattray, C Moung-Wen, Mary Campbell, Brian Piening, and Carlo Bifulco
Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system, Roshanthi Weerasinghe, Ryan Meng, Alexa K Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian D. Piening
Identifying tumor-reactive CD8+ TIL in patients with solid malignancies: clinical implications, Andrew D Weinberg
T Cell Agonists, Andrew D Weinberg
Design and Validation of a Whole-Genome SequencingBased Assay for Population Health, John Welle, Brian Piening, Josiah Wagner, I Lucas-Beckett, Thomas Ward, B Cosgrove, Eric Shull, R Rattray, Marina Pukay, Milena Ricks, K Childers, J Linehan, M Campbell, Ora Gordon, and Carlo Bifulco
Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy., Di Wen, Tingxizi Liang, Guojun Chen, Hongjun Li, Zejun Wang, Jinqiang Wang, Ruxing Fu, Xiao Han, Tianyuan Ci, Yuqi Zhang, Peter Abdou, Ruoxin Li, Linlin Bu, Gianpietro Dotti, and Zhen Gu
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors, Breelyn Wilky, Kim Margolin, Rachel E Sanborn, Steven O'Day, and See full list of authors in comments
Current Clinical Trial Landscape of OX40 Agonists., Rashi Yadav and William L. Redmond
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial., Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel E Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L. Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter Urba, Michael J. Gough, Marka R Crittenden, and Kristina H Young
1171 CAN1012: a selective and potent TLR7 agonist with strong antitumoral properties mediated by localized innate immune activation, Henry Yu, William L. Redmond, Yoshinobu Koguchi, and See all authors in comments
Submissions from 2021
Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production., Alejandro F Alice, Gwen Kramer, Shelly Bambina, Keith S Bahjat, Michael J Gough, and Marka R Crittenden
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma., Robert H I Andtbacka, Brendan Curti, Gregory A Daniels, Sigrun Hallmeyer, Eric D Whitman, Jose Lutzky, Lynn E Spitler, Karl Zhou, Praveen K Bommareddy, Mark Grose, Meihua Wang, Cai Wu, and Howard L Kaufman
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)., Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A Emens, Robert Ferris, Silvia C Formenti, Jerome Galon, Samir N Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M Paulos, Janis M Taube, John Timmerman, Bernard A Fox, Patrick Hwu, and Igor Puzanov
The State of Melanoma: Emergent Challenges and Opportunities., Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gerhsenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, and Glenn Merlino
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134, Michael B. Atkins, Brendan Curti, and See full list of authors in comments
Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth., Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James Wooldridge, William L. Redmond, and Scott W Rowlinson
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin
SARS-CoV-2 antibodies detected in human breast milk postvaccination, Jill K. Baird, Shawn M. Jensen, Walter Urba, Bernard A Fox, and Jason R Baird
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments
10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough
165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing, Devin Bridgen, Andrew D Weinberg, and See full list of authors in comments
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies., Samantha Brown, Jessica A Lavery, Ronglai Shen, Axel S Martin, Kenneth L Kehl, Shawn M Sweeney, Eva M Lepisto, Hira Rizvi, Caroline G McCarthy, Nikolaus Schultz, Jeremy L Warner, Ben Ho Park, Philippe L Bedard, Gregory J Riely, Deborah Schrag, Katherine S Panageas, AACR Project GENIE Consortium, Walter Urba, Brady Bernard, Brian D. Piening, and Carlo Bifulco
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors., Howard A. Burris III, Alexander I. Spira, and Matthew H Taylor
Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment., Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E Wirz, and Zhen Gu
Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study., Leo Chen, Caroline H Speers, Winson Y Cheung, John J Spinelli, and Hagen F Kennecke
Secondary Correction of Midface Fractures., Jonathan Chodroff, Nadir Elias, Michael Whitcomb, Cong Vo, and Richard Bryan Bell
94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2., Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, and Janice P Dutcher
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings., Roger B. Cohen, George E. Peoples, Rachel E Sanborn, and See list of authors in comments
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors., Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, and George N Pavlakis
Combinations of stereotactic radiotherapy and immune checkpoint inhibition: Translational analyses, Marka R Crittenden
Integrating Radiation Therapy with Immunotherapy, Marka R Crittenden
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor., Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, and William L Redmond
381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study, Brendan Curti and See full list of authors in comments
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma., Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Karl D Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I Spira, Daniel C Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L Currie, Wei Lin, Mary A Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michael E Hurwitz
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors., Khanh T Do, Laura Quan Man Chow, Karen Reckamp, Rachel E Sanborn, Howard Burris, Francisco Robert, D Ross Camidge, Conor E Steuer, John H Strickler, Amy Weise, Jennifer M Specht, Martin Gutierrez, Peter Haughney, Shawna Hengel, Christina Louise Derleth, and Timothy A Yap
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up., Charles W Drescher, Adam J Bograd, Shu-Ching Chang, Roshanthi Weerasinghe, Ann Vita, and Richard Bryan Bell
The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation., Shaan Dudani, Horia Marginean, Joanna Gotfrit, Patricia A Tang, Jose Gerard Monzon, Kristopher Dennis, Hagen F Kennecke, Erin D Powell, Sam Babak, Winson Y Cheung, and Michael M Vickers
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells., Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom Leidner, Brendan Curti, Bernard A Fox, Walter Urba, Richard Bryan Bell, and Andrew D Weinberg
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer., Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney, and Jennifer K Litton
Enhancing the generation of Eomeshi CD8+ T cells augment the efficacy of OX40- and CTLA-4-targeted immunotherapy., Dana A Emerson, Annah S Rolig, and William L. Redmond
383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695, Pablo Fernandez-Penas, Carmen Ballesteros-Merino, Shawn M. Jensen, Bernard A Fox, and See full list of authors in comments
Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311)., Robert L. Ferris, Yael Flammand, Richard Bryan Bell, and See list of authors in comments
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial., Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens, Chrisann Kyi, William Sharfman, Christine H Chung, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Lazar Vujanovic, Janis M Taube, Julie E Stein, Jun Li, Bin Li, Tian Chen, Adam Barrows, and Suzanne L Topalian
Evaluating the cancer surfaceome: a possible strategy to identify targets and monitor immunity, Bernard A Fox
Exploiting Autophagy and the Ubiquitin Pathway to Educate the Immune System and Improve Cancer Immunotherapy, Bernard A Fox
Translation: An Iterative and Team Process – Our Path to the Development of Triplet Cancer Immunotherapy, Bernard A Fox
